OncoMed Pharmaceuticals Inc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net loss
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Gain on disposal of equipment
Stock-based compensation
Amortization of discount on short-term investments
Changes in operating assets and liabilities:
Receivable-related parties
Accounts receivable and other receivables
Income tax refund receivable
Prepaid and other current assets
Other assets
Deferred tax assets
Accounts payable
Accrued liabilities, income tax payable and other liabilities
Accrued clinical liabilities
Deferred revenue
Deferred rent
Income tax payable

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of equipment
Purchases of short-term investments
Maturities of short-term investments
Net cash provided by (used in) investing activities

Financing activities
Proceeds from issuance of common stock related to the exercise of options and employee stock plan purchases
Net (decrease) increase in cash
Cash at beginning of year
Cash at end of year
Net proceeds from issuance of common stock
At-the-Market Offering
Public Offering
Net cash provided by financing activities
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental cash flow information:
Accrued liabilities for purchase of property and equipment
Cash paid for income taxes, net

Comments